188677-49-8

Usage

Uses

Used in Organic Synthesis:
3-IODOISONICOTINIC ACID METHYL ESTER is used as a building block for the synthesis of more complex organic molecules. Its unique structure allows for the formation of a variety of compounds, making it a valuable component in the development of new chemical entities.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 3-IODOISONICOTINIC ACID METHYL ESTER is utilized as an intermediate in the production of various drugs. Its presence in the synthesis process contributes to the development of medications with diverse therapeutic applications.
Used in Medicinal Chemistry Research:
3-IODOISONICOTINIC ACID METHYL ESTER is used as a subject of interest in the field of medicinal chemistry. Its potential biological and pharmacological activities are being studied to explore its possible applications in the discovery and development of new therapeutic agents.

InChI:InChI=1/C7H6INO2/c1-11-7(10)5-2-3-9-4-6(5)8/h2-4H,1H3

Upstream product

• 55279-30-6 methyl 3-aminoisonicotinate 
• 67-56-1 methanol 
• 57842-09-8 3-iodo-isonicotinanilide 
• 3034-31-9 N-phenylisonicotinamide 
• 7579-20-6 3-Aminopyridine-4-carboxylic acid 
• 57842-10-1 3-iodo-4-pyridinecarboxylic acid 
• 74-88-4 methyl iodide 

Downstream Products

• 1192019-22-9 2-(3-ethylpyridin-4-yl)-5-(trifluoromethyl)benzoxazole 
• 1192019-19-4 2-(3-phenyl pyridin-4-yl)-5-(trifluoromethyl)benzoxazole 
• 1192021-11-6 N-[2-hydroxy-5-(trifluoromethyl)phenyl]-3-iodoisonicotinamide 
• 57842-10-1 3-iodo-4-pyridinecarboxylic acid 
• 1160262-11-2 methyl 3-(3,4-dichlorophenyl)pyridine-4-carboxylate monohydrochloride 
• 570397-03-4 4-(1-methoxycarbonyl-3-methylsulfanyl-propylcarbamoyl)-5-o-tolyl-3,6-dihydro-2H-pyridine-1-carboxylic acid 3-cyclohexyl-1-thiazol-5-yl-propyl ester 
• 355008-64-9 2-{[1-(benzyl-thiazol-5-ylmethyl-carbamoyl)-5-o-tolyl-1,2,3,6-tetrahydro-pyridine-4-carbonyl]-amino}-4-methylsulfanyl-butyric acid methyl ester 

Relevant academic research and scientific papers

Enabling Efficient Positron Emission Tomography (PET) Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) with a Robust and One-Step Radiosynthesis of a Highly Potent 18F-Labeled Ligand ([18F]UCB-H)

We herein describe the straightforward synthesis of a stable pyridyl(4-methoxyphenyl)iodonium salt and its [18F] radiolabeling within a one-step, fully automated and cGMP compliant radiosynthesis of [18F]UCB-H ([18F]7), a PET tracer for the imaging of synaptic vesicle glycoprotein 2A (SV2A). Over the course of 1 year, 50 automated productions provided 34 ± 2% of injectable [18F]7 from up to 285 GBq (7.7 Ci) of [18F]fluoride in 50 min (uncorrected radiochemical yield, specific activity of 815 ± 185 GBq/μmol). The successful implementation of our synthetic strategy within routine, high-activity, and cGMP productions attests to its practicality and reliability for the production of large doses of [18F]7. In addition to enabling efficient and cost-effective clinical research on a range of neurological pathologies through the imaging of SV2A, this work further demonstrates the real value of iodonium salts for the cGMP 18F-PET tracer manufacturing industry, and their ability to fulfill practical and regulatory requirements in that field.

Biarylaniline phenethanolamines as potent and selective β3 adrenergic receptor agonists

The synthesis of a series of phenethanolamine aniline agonists that contain an aniline ring on the right-hand side of the molecule substituted at the meta position with a benzoic acid or a pyridyl carboxylate is described. Several of the analogues (e.g.,

PIPERIDINE COMPOUND AND PROCESS FOR PREPARING THE SAME

The present invention is to provide a piperidine compound represented by the formula [I]: wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted benzene ring, R1 is hydrogen atom or a substituent for amino

Aryl tetrahydropyridine inhibitors of farnesyltransferase: Glycine, phenylalanine and histidine derivatives

Inhibitors of farnesyltransferase are effective against a variety of tumors in mouse models of cancer. Clinical trials to evaluate these agents in humans are ongoing. In our effort to develop new farnesyltransferase inhibitors, we have discovered a series of aryl tetrahydropyridines that incorporate substituted glycine, phenylalanine and histidine residues. The design, synthesis, SAR and biological properties of these compounds will be discussed.

Inhibitors of protein isoprenyl transferases

The present invention relates to novel compounds of Formula I which are useful in inhibiting protein isoprenyl transferases and the farnesylation or geranylgeranylation of the oncogene protein Ras and other related small g-proteins, and compositions containing such compounds and methods of using such compounds.

Application of organolithium compounds in organic synthesis. Part 19. Synthetic strategies based on aromatic metallation. A concise regiospecific synthesis of 3-halogenated picolinic and isonicotinic acids

The synthesis of the halogenated picolin- and isonicotinalides (3) and (4) via metallation (n-BuLi) of the anilides (1) and (2) and then the reaction of the generated bis-lithiated anilides with halogenating agents (CCl3-CCl3, CH2Br-CH2Br, I2) followed by subsequent acidic hydrolysis of (3) and (4), as a way of regiospecific transformation of picoline and isonicotine acids into their C3-halogenated derivatives, is described.